The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy

(2013) Seung Tae Kim et al.   Cancer Research and Treatment

Influence ofKRASmutation status in metachronous and synchronous metastatic colorectal adenocarcinoma

(2012) Jeffrey S. Rose et al.   CANCER

Is K-ras Gene Mutation a Prognostic Factor for Colorectal Cancer

(2012) JiaoJiao Ren et al.   DISEASES OF THE COLON & RECTUM

Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population

(2011) Jyh-Ming Liou et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab

(2010) Li-Chen Yen et al.   ANNALS OF SURGERY

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies

(2010) Li-Xin Qiu et al.   EUROPEAN JOURNAL OF CANCER

Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer

(2010) Inti Zlobec et al.   INTERNATIONAL JOURNAL OF CANCER

Increased epidermal growth factor receptor expression at the invasive margin is a negative prognostic factor in colorectal cancer

(2010) Ingrid Ljuslinder et al.   INTERNATIONAL JOURNAL OF CANCER

High Epidermal Growth Factor Receptor Expression in Metastatic Colorectal Cancer Lymph Nodes May Be More Prognostic of Poor Survival Than in Primary Tumor

(2009) Yanhong Deng et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Detection of KRAS Oncogene in Peripheral Blood as a Predictor of the Response to Cetuximab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer

(2009) L.-C. Yen et al.   CLINICAL CANCER RESEARCH

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

(2009) Rafal Wierzbicki et al.   INVESTIGATIONAL NEW DRUGS

KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

(2009) Susan D. Richman et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

(2009) Arnaud D. Roth et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE